Close Menu

NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Wednesday that its fourth quarter revenues fell 23 percent year over year, largely due to a drop in sample accessions compared to same quarter last year.

For the three months ended Dec. 31, the company reported that its Q4 revenues fell to $995,226, compared to $1.3 million for Q4 2016. This included $61,000 from development services testing and $935,000 from commercial tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.